The cross-talk between LncRNAs and JAK-STAT signaling pathway in cancer

Ahmed Hjazi1, Rasha Fadhel Obaid2, Sally Saad Ali3

  • 1Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam bin Abdulaziz University, Al-Kharj 11942, Saudi Arabia.

Insights

Long non-coding RNAs (lncRNAs) regulate gene expression and impact cancer development by influencing the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway. Understanding this complex interplay offers potential new therapeutic targets for cancer treatment.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Genetics

Background:

  • Long non-coding RNAs (lncRNAs) are key regulators of gene expression involved in cellular activities.
  • Emerging evidence links lncRNAs to tumorigenesis, particularly through modulation of the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) pathway.

Purpose of the Study:

  • To review the reciprocal regulation and functions of lncRNAs and the JAK-STAT signaling pathway in cancer.
  • To highlight recent research advancements in this association.

Main Methods:

  • Literature review of studies investigating lncRNA and JAK-STAT pathway interactions in cancer.
  • Analysis of how lncRNAs modulate JAK-STAT signaling components and downstream effectors.
  • Examination of the dual role of lncRNAs in tumorigenesis and tumor suppression.

Main Results:

  • lncRNAs can directly or indirectly influence the JAK-STAT pathway, affecting cell proliferation, apoptosis, migration, invasion, and epithelial-mesenchymal transition.
  • lncRNAs can also act as downstream effectors of the JAK-STAT pathway, mediating tumorigenesis.
  • The specific relationship between lncRNAs and JAK-STAT signaling varies across different cancer types.

Conclusions:

  • The interplay between lncRNAs and the JAK-STAT pathway is complex and context-dependent in cancer.
  • Further understanding of this association may identify novel therapeutic targets for clinical intervention in cancer treatment.

Related Concept Videos

The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.7K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.7K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.8K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K